Westminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
Westminster Pharmaceuticals is recalling specific lots of Irbesartan Tablets because FDA testing found traces of NDEA impurity.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for significant health risks.
Plain-English summary
Westminster Pharmaceuticals, LLC is recalling specific lots of Westminster Irbesartan Tablets, USP 300 mg. The affected products are available in 30-count and 90-count bottles and were distributed nationwide. The recall involves 3,976 bottles with specific batch numbers and expiration dates listed in the agency's structured data.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. FDA laboratory testing confirmed the presence of traces of NDEA impurity in the specific lots of Irbesartan.
Consumers who have these specific products should stop using them and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- Westminster Irbesartan Tablets, USP 300 mg Rx Only Manufactured by: ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Manufactured for: Westminster Pharmaceuticals, LLC. Olive Branch, MS 38654 a) 30 count bottle NDC 69367-121-01; b) 90 count bottle NDC 69367-121-03
- Manufacturer
- Westminster Pharmaceuticals Llc
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 3,976
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batch Numbers: a) B162008A Exp. 09/30/2019
- C162002A Exp. 02/29/2020
- b) B162008B Exp. 09/30/2019
- C162002B Exp. 02/29/2020
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Westminster Pharmaceuticals Llc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Westminster Pharmaceuticals Llc
See all →- HighMetoprolol tartrate tablets recalled for nitrosamine above acceptable daily intake level
FDA (Drugs) · 2025-08-20
- HighMetoprolol tartrate 100 mg tablets exceed the nitrosamine daily intake level
FDA (Drugs) · 2025-08-20
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- SevereWestminster Irbesartan Tablets Recalled Due to NDEA Impurity Traces
FDA (Drugs) · 2018-12-19
- CriticalFDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
FDA (Drugs) · 2018-08-29
Same hazard · ndeA impurity
See all →- SevereMylan Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19
- SevereTeva Recalls Amlodipine and Valsartan Tablets Due to NDEA Impurity
FDA (Drugs) · 2018-12-19